Last reviewed · How we verify

LAIS®

Ajou University School of Medicine · FDA-approved active Small molecule

LAIS is a sustained-release intracameral steroid injection that delivers dexamethasone directly into the anterior chamber of the eye to reduce inflammation.

LAIS is a sustained-release intracameral steroid injection that delivers dexamethasone directly into the anterior chamber of the eye to reduce inflammation. Used for Post-operative inflammation following cataract surgery, Anterior uveitis.

At a glance

Generic nameLAIS®
Also known asactive treatment
SponsorAjou University School of Medicine
Drug classIntracameral corticosteroid implant
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

LAIS (Levotas Aqueous Implant System) is a biodegradable intracameral implant designed to provide prolonged corticosteroid delivery to the anterior segment of the eye. By releasing dexamethasone directly into the aqueous humor over an extended period, it maintains therapeutic anti-inflammatory levels while minimizing systemic exposure and the need for frequent topical dosing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: